Autologous CAR-T Cells Targeting CSPG4 therapy (Unc Lineberger Comprehensive Cancer Center)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAutologous CAR-T Cells Targeting CSPG4 therapy (Unc Lineberger Comprehensive Cancer Center)
Drug Alias NameiC9-CAR.CSPG4 T
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionChondroitin sulfate proteoglycan 4 modulatorsT lymphocyte replacements
TargetsChondroitin sulfate proteoglycan 4
Therapy Area/IndicationsHead and Neck NeoplasmsSarcomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals IncUnc Lineberger Comprehensive Cancer CenterCandiolo Cancer Institute - Irccs
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsSarcoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A